Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer

Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer

header-info

William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the importance of understanding tumor biology before choosing a treatment option.